Research map: Identifying facility-level and infrastructure-level bottlenecks in Japan's lecanemab rollout through an online survey of dementia specialists

Back to the article

Papers in this map

  1. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease · Clifford R. Jack · 2018 · 10916 citations · Cited by this paper
  2. Retinal thickness is associated with global cognition and executive function in mild cognitive impairment due to Alzheimer's disease · 2026 · Related
  3. Lecanemab in Early Alzheimer’s Disease · Christopher H. van Dyck · 2022 · 5709 citations · Cited by this paper
  4. Spermidine protects mitochondria against amyloid-β oligomers · 2026 · Related
  5. Lecanemab: Appropriate Use Recommendations · Jeffrey L. Cummings · 2023 · 915 citations · Cited by this paper
  6. Machine learning-based screening for Ascertain Dementia 8-defined suspected cognitive impairment leveraging routine health check data in South China · 2026 · Related
  7. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup · Reisa Anne Sperling · 2011 · 860 citations · Cited by this paper
  8. Diagnostic challenges in early-onset Alzheimer's disease: Case report of a patient with PSEN1 p.Asn135Ser mutation · 2026 · Related
  9. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging · Rioghna R. Pittock · 2023 · 151 citations · Cited by this paper
  10. Exploring potential genetic correlation and causality between cathepsins and neurodegenerative diseases: Insight from Mendelian randomization analyses · 2026 · Related
  11. Advances in Alzheimer's disease research over the past two decades · Clifford R. Jack · 2022 · 85 citations · Cited by this paper
  12. Brain transcriptome-wide association study reveals selective long-term potentiation enrichment and negative directional skew of senescence-regulation pathways in Alzheimer's disease · 2026 · Related
  13. Preparing for disease-modifying therapies in Alzheimer's disease · Christopher R S Belder · 2023 · 81 citations · Cited by this paper
  14. Screening of herbs for vascular dementia: Through the combination of reverse network pharmacology and traditional Chinese medicine enrichment analysis · 2026 · Related
  15. Projecting prevalence of frailty and dementia and the economic cost of care in Japan from 2016 to 2043: a microsimulation modelling study · Megumi Kasajima · 2022 · 78 citations · Cited by this paper
  16. Smaller pineal volume in Alzheimer's disease than in dementia with Lewy bodies · 2026 · Related
  17. A flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors · Michael J. Crowther · 2022 · 70 citations · Cited by this paper
  18. Does depression in Alzheimer's disease show evidence of differential gene expression in neurons or microglia compared to Alzheimer's disease without depression? · 2026 · Related
  19. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta‐analysis · Mohammad Khalafi · 2024 · 66 citations · Cited by this paper
  20. Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center · Lisa B. E. Shields · 2024 · 56 citations · Cited by this paper
  21. Cost-effectiveness of Alzheimer’s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis · José Contador · 2022 · 38 citations · Cited by this paper
  22. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease · Michelle Jin · 2024 · 26 citations · Cited by this paper
  23. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare · Karin E. Wahlberg · 2023 · 25 citations · Cited by this paper
  24. Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer’s Disease in Japan · Kenichiro Sato · 2024 · 16 citations · Cited by this paper
  25. Alzheimer's Association launches ALZ‐NET: A long‐term data collection and sharing network for new treatments · 2022 · 15 citations · Cited by this paper
  26. Real‐world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers · Kenichiro Sato · 2025 · 14 citations · Cited by this paper
  27. Advertisement by medical facilities as an opportunity route of APOE genetic testing in Japan: a website analysis · Kenichiro Sato · 2024 · 7 citations · Cited by this paper
  28. Lecanemab: Experts criticise European Commission approval of Alzheimer’s drug · Gareth Iacobucci · 2025 · 7 citations · Cited by this paper
  29. How will the emergence of lecanemab change dementia treatment? · Atsushi Iwata · 2024 · 6 citations · Cited by this paper
  30. Implementation of Lecanemab for Alzheimer's Disease Within the Veterans Health Administration: Facilitators and Barriers · Alison J. O’Donnell · 2025 · 5 citations · Cited by this paper
  31. Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study · Kazuki Ohashi · 2024 · 3 citations · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)